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Abstract
GNRH significantly inhibits proliferation of a proportion of cancer cell lines by activating
GNRH receptor (GNRHR)-G protein signaling. Therefore, manipulation of GNRHR signaling
may have an under-utilized role in treating certain breast and ovarian cancers. However, the
precise signaling pathways necessary for the effect and the features of cellular responses
remain poorly defined. We used transcriptomic and proteomic profiling approaches to
characterize the effects of GNRHR activation in sensitive cells (HEK293-GNRHR, SCL60)
in vitro and in vivo, compared to unresponsive HEK293. Analyses of gene expression
demonstrated a dynamic response to the GNRH superagonist Triptorelin. Early and mid-
phase changes (0.5–1.0 h) comprised mainly transcription factors. Later changes (8–24 h)
included a GNRH target gene, CGA, and up- or downregulation of transcripts encoding
signaling and cell division machinery. Pathway analysis identified altered MAPK and cell
cycle pathways, consistent with occurrence of G2/M arrest and apoptosis. Nuclear factor
kappa B (NF-kB) pathway gene transcripts were differentially expressed between control and
Triptorelin-treated SCL60 cultures. Reverse-phase protein and phospho-proteomic array
analyses profiled responses in cultured cells and SCL60 xenografts in vivo during Triptorelin
anti-proliferation. Increased phosphorylated NF-kB (p65) occurred in SCL60 in vitro, and
p-NF-kB and IkB3 were higher in treated xenografts than controls after 4 days Triptorelin.
NF-kB inhibition enhanced the anti-proliferative effect of Triptorelin in SCL60 cultures.
This study reveals details of pathways interacting with intense GNRHR signaling, identifies
potential anti-proliferative target genes, and implicates the NF-kB survival pathway as a
node for enhancing GNRH agonist-induced anti-proliferation.
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Introduction
GNRH analog therapy is used in the treatment of
hormone-dependent cancers, such as prostate and breast
cancers, to suppress androgen and estrogen production.
In addition, GNRH agonists and antagonists have direct
anti-proliferative effects (independent of their hormone
regulatory actions) on various reproductive tissue cancer
cell lines from prostate (Limonta et al. 1992, 2012, Moretti
et al. 1996, Angelucci et al. 2004, Morgan et al. 2011a),
breast (Blankenstein et al. 1985, Miller et al. 1985, Eidne et al.
1987, Marini et al. 1994, Emons et al. 2003, Finch et al. 2004),
ovary (Emons et al. 1989, 1993b, Grundker et al. 2000, 2001,
2002, Maudsley et al. 2004), and endometrium (Emons et al.
1993a, Grundker et al. 2001, 2002, Acharya et al. 2008).
Depending on the cellular phenotype, intense signaling
from activated GNRH receptor (GNRHR) can induce cell
cycle arrest in G2, with or without concomitant induction
of apoptosis. The activated receptor couples to Gq/11 and
elicits rapid transient phospholipase C activation, mobil-
ization of intracellular calcium (via inositol trisphosphate
(IP3)), protein kinase C activation (via diacylglycerol (DAG))
and activation of MAP kinase, and stress-activated kinase
signaling (ERK, JNK, and p38) (Morgan et al. 2008). A role
for Gi has been proposed by various investigators but
has yet to be critically tested beyond the application
of pertussis toxin in co-treatment assays and this contrasts
with a crucial role for Gq/11(White et al. 2008).
Although inappropriate signaling results in cellular
stress, the details concerning how this stress is converted
into a commitment to growth arrest and/or apoptosis are
largely uncharacterized. The cellular response is likely to be
complex, with changes in gene transcription and regulation
of proteins affecting functions of key importance to cell fate.
More details concerning the response to GNRHR activation
are required in order to understand the anti-proliferative
mechanism and to explain why certain cells are more
sensitive than others, even though they express similar
levelsofGNRHR (Morgan etal. 2008). A high level ofGNRHR
expression at the cell surface correlates with responsiveness
to GNRH (Morgan et al. 2008), supporting the hypothesis
that there is a requirement for direct interaction between
GNRHR and agonist at the cell surface. Identifying the
determinants of sensitivity to GNRH analogs would poten-
tially allow sensitive tumors to be selected for treatment.
In order to identify signaling factors required for
response to the potent GNRH superagonist, Triptorelin,
we employed transcript profiling and protein array
analysis of the model human HEK293 (SCL60) cells
in vitro and in tumor xenografts to identify markers likely
to reflect the anti-proliferative mechanism. This model is a
HEK293 cell line transfected with a high level of the
GNRHR (Morgan et al. 2008). In most published studies of
cancer cells, the presence of GNRHR is inferred on the
basis of RT-PCR detection of mRNA and/or by detection of
ligand binding to whole cell lysates. In those instances,
detection of GNRHR mRNA cannot reliably indicate how
much functional GNRHR is present and ligand binding
assays usually need to be pushed to the limit of detection
sensitivity to infer specific GNRH analog binding. Using
HEK293 cells transfected to overexpress GNRHR circum-
vents these problems and direct comparison can be made
to wild-type HEK293 cells. The utility of transfected cell
studies has been re-iterated recently (Morgan et al. 2011b).
Our strategy extends preliminary data generated using
mouse pituitary tumor LbT2 (White et al. 2008), which
serves as a useful benchmark comparison (Morgan et al.
2008). We discovered dynamic changes in gene transcrip-
tion and altered protein phosphorylation in pathways,
which shed more light on the anti-proliferative
mechanism of GNRHR activation, and suggest ways in
which its effectiveness may be improved.
Materials and methods
Cell lines
SCL60 cells are HEK293 cells stably transfected with a high
level of functional rat GNRHR (Morgan et al. 2008). SCL60
cells express surface levels of GNRHR similar to that of
GNRHR at the surface of mouse embryo pituitary
gonadotrope cell line LbT2 (White et al. 2008). This level
is similar to that found in mature pituitary gonadotrope
cells and at least 100-fold higher than surface receptor
levels in any cancer cell line thought to express endo-
genous GNRHR (Morgan et al. 2008, 2011a).
SCL215 cells stably express a rat GNRHR fused to a
catfish GNRHR C-terminal cytoplasmic domain (under
G418 selection). The fusion protein binds GNRH analogs,
but this does not activate signaling.
HEK293, SCL60, and SCL215 cells were cultured
in DMEM with 10% fetal bovine serum. SCL60 and
SCL215 cells were supplemented with G418 antibiotic
(0.5 mg/ml). For all these cell lines, tissue culture plates
were coated with a diluted Matrigel solution (200 ml Matrigel
(BD Biosciences, Oxford, UK) per 6 ml DMEM media, 22 8C
for 1–2 h, excess removed before adding cells) to assist
cell adherence. Cell doubling times for each of the cell lines
in basal conditions are similar (w22 h).
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research C Meyer et al. Anti-proliferative GNRH signaling 20 :1 124
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-12-0192
q 2013 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
In vitro gene expression profiling
SCL60 or HEK293 cells were treated with 100 nM Triptorelin
(Sigma), or an appropriately diluted 20% propylene glycol
(Sigma) solution (final concentration: 0.02% propylene
glycol). RNA was isolated at 0, 0.5, 1, 2, 8, and 24 h after
treatment from four independent experiments on different
days using the Absolutely RNA Miniprep kit (Stratagene,
Leicester, UK) according to the manufacturer’s instructions.
Purified RNA was biotin labeled using the Illumina TotalPrep
RNA Amplification Kit (Ambion, Huntingdon, UK) according
to the manufacturer’s instructions. Labeled RNA was hybri-
dized to Illumina HT12 BeadChips and scanned at the
Wellcome Trust Clinical Research Facility, Western General
Hospital, Edinburgh. The gene expression data have been
submitted to NCBI’s Gene Expression Omnibus and is
accessible through GEO Series accession number GSE27467.
Geneexpressionanalysiswasperformedusingtheopensource
statistical programming language, R (Ihaka & Gentleman
1996), and associated Bioconductor packages (Gentleman
et al. 2004). Data were filtered to remove unreliably detected
probesand oneoutlier replicateandthen quantile-normalized
using theBeadarray (Dunning et al. 2007)package.Differential
expression was determined using Rank Products analysis
(Breitling et al. 2004) with 5% false discovery rate.
Flow cytometric DNA analysis
Cells were treated with Triptorelin (100 nM) or 0.02%
propylene glycol solution (vehicle control) for up to 72 h
before being trypsinized, pelleted, and resuspended in pH
7.6 citrate buffer. Samples were stored at K20 8C until
analysis and were then thawed to room temperature.
The cells were incubated at room temperature with
0.003% trypsin solution (450 ml; 0.003% trypsin, 3.4 mM
tri-sodium citrate, 0.1% NP40, 1.5 mM spermine hydro-
chloride, and 0.5 mM Tris base) for 2 min with agitation
and then with a second solution (375 ml; 0.05% trypsin
inhibitor, and 0.01% w/v RNase A) for 10 min. Finally,
cells were treated with 250 ml propidium iodide solution
(416 mg/ml propidium iodide, 1.16 mg/ml spermine tetra-
hydrochloride solution) on ice and in the dark for 10 min.
The samples were analyzed using a BD FACSAriaII SORP
Flow Cytometer (Becton Dickinson, Oxford, UK) and BD
FACSDiva software (Becton Dickinson, Version 6.1.2).
Xenograft tumors
Tumors were derived from the GNRHR-transfected
HEK293 cell line, SCL60, by s.c. bilateral implantation of
these cells into the flank of athymic nude female mice
(Morgan et al. 2008). Nine mice with 11 tumors were
treated with Triptorelin (10 mg/mouse, 0.1 ml). Ten mice
with 12 tumors were injected with a 20% propylene glycol
solution (0.1 ml). Treatment was initiated when tumors
were 50–100 mm3 in size. Xenograft material was collected
at days 4 and 7 after treatment.
Phosphoprotein antibody array
Samples from three tumors following treatment with
Triptorelin at day 4 and 7, along with six corresponding
controls, were analyzed using the V250 antibody array
(Eurogentec Ltd., Southampton, UK). This array comprises
117 pairs of antibodies to detect phosphorylated and non-
phosphorylated forms of proteins that are typically
dysregulated in cancer-related signaling. A full list of
antibodies used is shown in Supplementary Table 1, see
section on supplementary data given at the end of this
article. Binding of each antibody to its target results in
an emission fluorescence, whose intensity is proportional
to the level of the target protein. The intensity score for
each phosphorylated protein was normalized by Euro-
gentec Ltd. to that of its non-phosphorylated counterpart.
Immunohistochemistry
A tissue microarray (TMA) was constructed with five
Triptorelin-treated and six untreated SCL60 xenografts
in biological triplicate as described previously (Kononen
et al. 1998). Hydrated TMA sections were incubated
with primary antibody (rabbit anti-Cleaved Caspase 3
(Asp175; 1:100), rabbit anti-Phospho-Histone H3 (Ser10;
1:200), anti-nuclear factor kappa B (NF-kB) (1:00, Cell
Signaling), or anti-pNF-kB (1: Cell Signaling, Hitchin,
UK) for 1 h at room temperature and were detected via
DakoCytomation envision/HRP Kit (K4003) (Dako, Ely,
Cambridgeshire, UK). Finally, all the slides were counter-
stained in hematoxylin for 20 s, dehydrated, and mounted.
After staining, slides were observed by 400!magnification
and a histoscore per core per slide was calculated.
Reverse-phase protein array
Protein was isolated from SCL60, HEK293, and SCL215 cells
following treatmentwith Triptorelin (100 nM)orcontrol for
0, 0.5, 1, 2, 4, 8, or 24 h from three independent
experiments. Samples were diluted to 2 mg/ml and then
twofold serially diluted to produce five dilutions of each
sample. Each dilution was spotted (Spurrier et al. 2008) in
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triplicate onto each pad of a 2-pad FAST nitrocellulose-coated
glass slide (Whatman, Lutterworth, UK) using a BioRobo-
tics Microgrid (Isogen Life Science, De Meern, The Nether-
lands). Samples were carefully distributed over the pads to
ensure that a balance of control and treated samples was
spotted by each pin. Slides were blocked with PBS:Li-Cor
Blocking Buffer (1:1, 1 h RT) before incubation with
primary antibody (overnight 4 8C). Phosphoprotein (p)
expression was measured and compared with total (t)
levels of expression.
Primary antibodies were Rabbit polyclonal, from Cell
Signaling Technology UK, and diluted 1:50 unless
otherwise stated: Anti-P21 (mouse, 1:150), anti-tPTEN
(mouse, 1:300), anti-pPTEN (Ser80/Thr382/383), anti-
tmTOR (1:300), anti-pmTOR (Ser2448), anti-tCDK2,
anti-pCDK2, anti-tAKT (mouse, 1:1000), anti-pAKT
(Ser473), anti-tNF-kB, anti-pNF-kB (Ser529), anti-tCyclinD1
(mouse, 1:300), anti-pCyclinD1 (Thr286), Ki67 (Dako,
mouse, 1:250), anti-P38 (1:100), anti-pP38 (1:100), pHistone
H3 (Ser10, 1:100), PI3K p110a (1:133), pERa (mouse, 1:100),
tERa (Neomarkers, Maybridge, Tintagel, UK; 1:250), tCAV1,
pCav1 (Tyr14), pMet (Tyr1349), tMet (mouse), pCHK2
(Ser516), tERK (Thr 202/204 for ERK1 and Thr 185/187 for
ERK2) (mouse), pERK (1:100), P53 (mouse), and GNRHR
(Leica, mouse). Slides were washed with PBS–0.1%Tween 20
(3!5 min) before applying secondary antibody diluted in
Li-Cor blocking buffer (45 min RT, dark). The slides were
washed in the dark with PBS–0.1% Tween 20 (3!5 min),
PBS (3!5 min), and then dried at 50 8C. The slides were
scanned on a Li-Cor Odyssey scanner at 680 and 780 nm.
The image was analyzed using MicroVigene RPPA Analysis
module software (VigeneTech, Carlisle, MA, USA). The
means of the triplicate dilutions are used to produce a
curve for each sample. The y-intercept is used as a relative
measure of protein concentration between curves. This
quantitative measurement is used in further analysis.
Measurements for phosphoproteins were normalized to
the corresponding total protein except for Ki67 and pHH3.
Cell growth assays
SCL60 cells were seeded into 12-well plates at
1!106 cells/ml. After 48 h, the cells were washed in
serum-free media and then treated with 3 mM 15d-PGJ2
(NF-kB inhibitor) or vehicle control (dimethyl sulfoxide)
in serum-free media for 30 min before addition of 100 nM
Triptorelin or vehicle control (final concentration: 0.02%
propylene glycol) in complete media with serum. After
4 days, cell growth was measured by sulforhodamine B
assay as described previously (Skehan et al. 1990).
Results
GNRHR activation induces S phase and G2/M arrest in
GNRHR-expressing cells in vitro
Triptorelin elicited 63% inhibition of SCL60 cell growth
after 5 days of treatment but did not affect growth of
untransfected parental (HEK293) cells or those transfected
with an inactivating mutant GNRHR (SCL215) (Fig. 1A).
Flow cytometric analysis of the cells demonstrated that
the anti-proliferative effect of Triptorelin in SCL60 cells
was associated with an accumulation of cells in the S and
G2/M phases of the cell cycle at 24 and 48 h after treatment
compared with vehicle-treated control cells (Fig. 1B;
Supplementary Figure 1, see section on supplementary
data given at the end of this article). There was a
significant increase in cleavage of the caspase-mediated
apoptosis marker poly (ADP-ribose) polymerase (PARP;
Fig. 1C). This increase was small after 48-h treatment with
Triptorelin but was much more pronounced after 72–96 h
(Fig. 1C). These results reproduce reported results for
SCL60 cells (Morgan et al. 2008, 2011a).
Differential gene expression between GNRHR-expressing
(SCL60) and parental (HEK293) cells
To explore the baseline differences in GNRHR-mediated
signaling between these responsive and nonresponsive
cell lines, we compared the global gene expression profile
of the GNRHR-expressing SCL60 cell line with the parental
cell line, HEK293. Over 4700 probes were consistently
differentially expressed between replicate cultures of these
cell lines (w18% of detected probes on the microarray)
using Rank Products analysis with 5% false positive
rate). Genes that had higher expression in the GNRHR-
expressing cells included genes involved in adhesion
(CD44 and TACSTD1 (EPCAM)) and transcriptional
regulation (SOX11, TCEAL3, and RUNX3), while genes
that had significantly lower expression in SCL60 cells
compared with HEK293 cells encoded many transcription
regulators (including seven zinc finger proteins) and
several proteins involved in adhesion (PCDH17,
PCDH10, and SH3PXD2A) (Supplementary Table 1).
Dynamic transcriptional response to GNRHR activation
in vitro
We next assessed the effect of Triptorelin treatment on
gene expression in SCL60 cells before (0) and 0.5, 1, 2, 8,
and 24 h after treatment. The greatest number of
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differentially expressed genes (O1000) occurred after 8 h
treatment with Triptorelin (Fig. 2A), with a higher
proportion of genes upregulated rather than downregu-
lated at the early time points (0.5–2 h). Downregulated
genes were more apparent after 2 h, presumably reflecting
a secondary response, influenced in part by the primary
response. The online pathway annotation tool, DAVID
(Huang da et al. 2009), was used to determine which
pathways were significantly enriched among the genes
differentially expressed between SCL60 control and
treated cells. Genes that were increased following treat-
ment represented components of the cell cycle, MAPK and
p53 signaling pathways, whereas transcripts that were
decreased included cell cycle genes (Table 1). Clustering
the most strongly upregulated genes in response to
Triptorelin treatment in SCL60 cells showed at least
three clusters of temporal expression (Fig. 2B). The ‘early
genes’ (0.5–1 h) included early growth response 1 (EGR1),
the MAP kinase inactivator DUSP1 (MKP1), along with the
transcription factors JUNB, FOS, and FOSB (Fig. 2B). Genes
that were increased later (8–24 h) included the epithelial
cell stress chemokine, IL8, and the glycoprotein common
gonadotropin subunit alpha (CGA), a GNRH signaling
target gene in pituitary gonadotrope cells (Fig. 2B). The
most downregulated genes included the cell motility
SLIT-ROBO Rho GTPase activating protein SRGAP3, and
the growth factor modulator IGF binding protein 5
(Fig. 2C). These genes were also mostly lower in HEK293
cells compared with SCL60-untreated cells but were
unaffected by Triptorelin treatment in HEK293 cells
(Fig. 2C). Of the genes that were significantly higher in
SCL60 cells compared with HEK293 cells, 138 were also
consistently increased with Triptorelin treatment in
SCL60 cells, while 82 genes were downregulated after
treatment and higher in SCL60 cells compared with
HEK293 cells, including fibroblast growth factor receptor
(FGFR) and CACN (involved in calcium channel forma-
tion). Pathways associated with these genes included
MAPK and cell cycle signaling (full lists are given in
Supplementary Table 1). Looking more closely at the
timing and processes of transcripts altered by GNRHR
activation, it becomes clear that the changes classify into
several distinct temporal and functional groups (Fig. 3).
These patterns can be summarized as early sustained
changes in transcription factors (EGR1, FosB, Fos EGR2,
SRF, ATF3, and KLF6), G1/S markers (MCM8 and CHEK2),
and signaling apparatus – including regulators of inositol
phosphate metabolism and MAP kinase phosphatases
(DUSP5, DUSP1, INPP1, and ISYNA1); later and continu-
ing changes in G2/M markers (NDEL1, CDC2, TUBB4,
DCTN1, KIF20A, CENPM, CENPF, and RASSF1A) and
apoptotic apparatus (EIF5A, KLF10, BAX, and cFLAR);
and more transient changes in cytoskeletal components
Ce
lls
 re
la
tiv
e 
to
co
n
tro
l (%
)
R
at
io
 o
f c
el
ls 
in
 p
ha
se
 o
f
ce
ll 
cy
cle
 (r
ela
tiv
e t
o c
on
tro
l)
*
0
20
40
60
80
100
120
140 C = Vehicle control
T = Triptorelin (100 nM)
0.0
0.5
1.0
1.5
2.0
24 48 24 48 24 48
G0/G1
S
G2/M
SCL60 HEK293 SCL215
SCL60A
B
C
HEK293 SCL215
0
5
0 24 48 72 96
Time (h)
1
2
3
4
Ex
pr
es
sio
n 
in
 T
rip
to
re
lin
-
tre
at
ed
 re
la
tiv
e 
to
 c
on
tro
l
Cleaved PARP (CPARP)
Uncleaved PARP (UPARP)
CPARP
UPARP
Time (h)
C T C T C T
C C T C T C T C T
Figure 1
GNRH agonists reduce cell growth by cell cycle arrest and apoptosis in vitro.
(A) Cell growth measured by sulforhodamine B assay following treatment
with Triptorelin (100 nM) or vehicle control (0.02% propylene glycol) for
5 days. Bars show mean of three replicates. Error bars show S.D., *P!0.01.
(B) Flow cytometric cell cycle analysis of SCL60, HEK293, and SCL215 cell
lines following treatment with Triptorelin (100 nM) or vehicle control
(0.02% propylene glycol) demonstrates that the anti-proliferative effect is
characterized by cell cycle arrest. Data are expressed as a ratio of cells in
each cell cycle phase, after Triptorelin treatment, relative to vehicle control
samples. P values (paired t-test) for SCL60 triptorelin-treated vs control
groups at 24 and 48 h are G0/G1 phase, PZ0.025; S phase, PZ0.027; and for
G2/M phase, PZ0.015. (C) Western blot for caspase-mediated apoptosis
marker-cleaved PARP. Values for Triptorelin-treated samples are shown
relative to the corresponding vehicle control-treated samples at each time
point (black bars). Uncleaved PARP expression is also shown (white bars).
The lanes of the blot alternately show control and treated samples for
each time point respectively. N.B. Control and treated at the zero time
point are the same.
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GNRH agonist causes significant changes in gene expression over 24 h.
(A) The number of differentially expressed genes (Rank Products P!0.05)
in SCL60 cells peaks 8 h after Triptorelin treatment, full lists of genes are
in Supplementary Table 1. (B) The 25 most upregulated genes after
Triptorelin treatment in SCL60 cells. (C) The 25 most downregulated
genes after Triptorelin treatment in SCL60 cells (left), and the expression
of these genes in the HEK293 Triptorelin-treated and untreated cells
(right). Heatmaps represent changes in expression relative to the median
of untreated SCL60 replicate cells (Red, upregulated; green,
downregulated).
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(TPM4, ITGAV, KIF5C, FLRT3, DSTN, MAPT, and DGCR2)
and cyclins (CCNA1 and CGRRF1).
In order to establish whether the GNRHR-mediated
gene expression changes observed were similar to GNRH-
regulated changes in other systems, we compared them to
a previous study by Kakar et al. (2003). These investigators
reported a list of 68 genes whose expression was changed
in mouse LbT2 gonadotrope cells following treatment
with a GNRH agonist des-gly10, [D-Ala6]-ethylamide
GNRH. Human homologs could be identified for 59 of
the mouse genes and these were sufficient to cluster the
SCL60 dataset into treated and control groups. Of the
59 orthologous genes, 21 were commonly differentially
expressed, including a number of the early response
genes EGR1, FOSB, JUNB, and IER2 (Supplementary
Table 1), although this study was limited to 1- and 24-h
time points.
Dynamic phosphoproteomic response to GNRHR
activation
Building upon the gene expression data, reverse-phase
protein array (RPPA) technology was used as a screening
tool to characterize the posttranscriptional response to
GNRHR activation. The focus was on representative
members of cell cycle components, growth regulators,
MAPK signaling, and cell survival modulators, as these
were suggested to be important from the gene expression
data (Fig. 4A). Levels of pERK were increased, as expected
from previous studies (Morgan et al. 2008) and levels of
pNF-kB expression were also increased (Fig. 4B and C and
Supplementary Figure 3, see section on supplementary
data given at the end of this article). In contrast, pAkt
decreased in a more gradual manner and pPTEN
expression demonstrated a transient reduction (Fig. 4C
and Supplementary Figure 3). The level of p-histone H3
showed a reduction initially but was increased after 24 h
and may reflect cells accumulating in the G2/M phase of
the cell cycle. The overall reduction in pAkt and increases
in the levels of pERK and pNF-kB expression were
confirmed by western blot (Fig. 4B, C and D).
Triptorelin induces caspase-mediated apoptosis in SCL60
xenografts
We next assessed the effect of Triptorelin on GNRH
signaling in vivo. Consistent with previous findings
(Morgan et al. 2008), Triptorelin was found to cause a
significant reduction in growth of SCL60 xenograft tumors,
and we established that the GNRH agonist had no effect on
Table 1 Genes significantly increased and decreased with Triptorelin treatment in SCL60 cells were enriched for various signaling
pathways. The predicted false discovery rate (FDR) and one-tail Fisher Exact test P values were calculated within DAVID. Highlighted
genes (in bold) are among the 25 most increased or decreased probes (Fig. 2).
Genes P value FDR
Increased pathways
hsa04110: cell cycle CDK1, ANAPC10P1, CDC14A, CDC14B, CCNH, ANAPC10, CCNE2,
LOC440917, CCNB1, CDKN1A, YWHAG, MAD2L1, ORC6L, MDM2,
CCNA1, GADD45B, MYC, GADD45A, BUB3
0.001 0.75
hsa04115: p53 signaling pathway CCNE2, CCNB1, CDK1, CDKN1A, CASP9, RRM2, MDM2, PMAIP1,
GADD45B, SESN2, THBS1, GADD45A
0.001 1.7
hsa04621: NOD-like receptor
signaling pathway
MAP3K7, HSP90B1, CCL2, IL8, CXCL2, CCL8, NFKBIA, TRAF6, BIRC2,
CHUK, CCL7
0.002 2.8
hsa04010: MAPK signaling pathway MAPKAPK5, NFKB2, SRF, MAP3K7, FOS, DUSP14, JUND, MAP3K8, TRAF6,
MYC, CHUK, RELB, ATF4C, NR4A1, FLNC, DDIT3, DUSP5, ATF4, DUSP3,
DUSP1, RRAS2, LOC100133211, JUN, RAP1B, GADD45B, DUSP8, GADD45A
0.02 18
hsa04622: RIG-I-like receptor
signaling pathway
MAP3K7, DDX3X, ISG15, IL8, IL12A, NFKBIA, TRAF6, CHUK, AZI2, TANK 0.02 20
Decreased pathways
hsa04110: cell cycle E2F2, LOC100133012, CDC14B, CREBBP, PRKDC, MCM2, CHEK2, MCM4,
MCM5, LOC440917, RAD21, CDKN2A, EP300, MCM7, CDKN1B,
CDKN2B, LOC646096, LOC731751, ABL1
5!10K4 0.66
hsa04330: Notch signaling pathway NOTCH3, CTBP1, NOTCH1, EP300, APH1A, CREBBP, JAG2, NCOR2 0.005 6.1
hsa04012: ErbB signaling pathway LOC407835, CBLB, NRG4, CDKN1B, PAK2, PLCG1, ERBB3, MAP2K2,
CAMK2G, PLCG2, ABL1
0.02 19
hsa04310: Wnt signaling pathway WNT5A, FZD8, CTBP1, PPP2R5D, CAMK2G, CREBBP, VANGL2, FZD2,
FZD4, CTNNBIP1, EP300, PRICKLE1, FRAT2, TBL1X
0.02 23
hsa04512: ECM-receptor interaction SDC1, COL4A1, LAMA5, COL6A1, ITGB5, COL2A1, AGRN, COL4A6, HMMR 0.04 38
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Figure 3
Temporal changes in the expression of genes in response to Triptorelin
belong to different functional classes. Transcript expression can be
tentatively classified into groups of ‘early maintained’, ‘later, continued’, or
‘transient’ changes in response to Triptorelin (upper panel). Changes in
transcripts encoding components required in G1/s, G2/M, or cyclins and
the signaling apparatus downstream from the GNRH receptor are also
illustrated (middle and lower panels).
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parental (HEK293) or mutated receptor-transfected
(SCL215) cells (Fig. 5A). Immunostaining revealed
decreased levels of p-Histone H3, consistent with reduced
proliferation (Fig. 5B) and increased caspase 3, consistent
with increased apoptosis following Triptorelin treatment
for 4 and 7 days compared with untreated control tumors
(Fig. 5B, PZ0.004). Representative images are shown in
Supplementary Figure 2, see section on supplementary data
given at the end of this article.
Phosphoproteomic profiling the response to Triptorelin in
SCL60 xenograft tumors
To determine whether similar pathways were changed in
response to a GNRH agonist in vivo, we used an antibody
array with 117 pairs of antibodies (Supplementary Table 1)
to detect both the phosphorylated and non-phosphory-
lated forms of selected proteins in SCL60 xenografts
treated with Triptorelin. There were increases in phos-
phorylation of both NF-kB-p65 and IkB3 after 4 days,
consistent with the RPPA in vitro analysis and suggesting a
possible involvement of the NF-kB survival signaling
pathway in response to Triptorelin treatment. Also
consistent with the RPPA data was the reduction in
phosphorylated Akt at day 7. Changes observed in Chk2,
p27, and CDC25C may be representative of the disruption
to cell cycle progression. Dynamic changes in levels of
phosphoproteins occurred: these included a gradual
decrease in pMET, a transient increase in AMPK1, and a
sustained increase in pMYC (Fig. 5C).
Inhibition of NF-kB enhances the anti-proliferative effect
of GNRHR activation
As both in vitro RPPA and in vivo phosphoprotein array data
highlighted that NF-kB signaling was activated in response
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Figure 4
Reverse-phase protein array expression implicates changes in pERK, pAkt,
and pNF-kB in the response to Triptorelin. (A) Changes in cancer-
associated proteins following Triptorelin treatment for 0.5, 1, 2, 4, 8, and
24 h. Phosphoproteins are prefixed with lower case ‘p’ and their data are
normalized to that of the corresponding total protein. Red, increased;
Green, decreased. Changes in pERK1/2 (B), pNF-kB (C), and pAkt (D) were
confirmed by western blot. Blots aligned below each time point are for
control (left) and treated (right) respectively. Control and treated at the
zero time point are the same. The increases in pERK and pNF-kB and
decrease in pAKT observed in these individual western blots were also
observed in parallel RPPA experiments (Supplementary Figure 3).
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to Triptorelin treatment, we investigated the in vitro gene
expression patterns of several NF-kB pathway members
in SCL60 cells following treatment with Triptorelin
(Fig. 6A). NF-kB1 expression peaked at 8 h, whereas
NF-kBIA and MAPK8 (an activator of NF-kB-p105) were
highest after just 2 h, while gene expression levels of
IKBKG and IKBKB were largely unchanged. To validate the
increase in pNF-kB seen upon GNRH stimulation in vivo,
we next performed immunohistochemistry on the xeno-
graft tumors and found pNF-kB to be significantly
(PZ0.009) higher following treatment with Triptorelin
(Fig. 6B). Representative images are shown in
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Figure 5
Triptorelin reduces tumor volume and proliferation while increasing
apoptosis in vivo. Phosphoproteomic signaling highlights a number of
pathways including NF-kB. (A) Tumor volume changes relative to day 0.
Data are mean values of at least nine control xenograft tumors and nine
Triptorelin-treated tumors. Error bars showGS.E.M. 10 mg Triptorelin/mouse
for up to 14 days. Initial tumor volumes at start of treatment were 73 (G11)
mm3 for SCL60, 86 (G11) mm3 for SCL60, and 84 (G7) mm3 for HEK 293
xenografts. There was a reduction in proliferation, shown by phospho-
histone H3 (B), and an increase in apoptosis, shown by cleaved caspase 3
after 4 and 7 days. (C) Phosphoproteomic antibody arrays demonstrated
changes in a number of phosphoproteins following Triptorelin treatment
in vivo (Red, increased phosphorylation; Green, decreased phosphoryl-
ation); only those phosphoproteins that demonstrated a significant
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Control; Closed grey triangle, Triptorelin.
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Supplementary Figure 4, see section on supplementary
data given at the end of this article.
To evaluate NF-kB signaling as a possible pathway
to target in combination with GNRHR activation,
we inhibited the pathway in SCL60 cells in vitro. After
4 days, we observed significant reduction of SCL60 cell
growth when treated with either 100 nM Triptorelin or
3 mM 15d-PGJ2 (NF-kB inhibitor) (Straus et al. 2000) and
enhanced growth repression when both were used in
combination (Fig. 6C), suggesting an additive effect. In
contrast, none of these treatments influenced the growth
of the parental HEK293 cells.
Discussion
Various G protein-coupled receptors (GPCRs) at the cell
surface can influence cancer cell growth. Intense acti-
vation of the GNRHR, a Gq/11-coupled peptide hormone
GPCR, can inhibit the proliferation of certain but not all
cancer cell types. An improved understanding of how
GNRH agonist anti-proliferative effects are elicited could
address how certain cells are able to avoid the resulting
downstream growth arrest signaling and treatment could
be tailored more appropriately. Detailing the cellular
responses to GPCR activation is a difficult process due to
signaling pathway complexity and the temporal changes
that occur downstream from receptor activation. In this
study, we used global gene and protein expression
approaches to explore GNRHR signaling in relation
to cell growth inhibition. We identified a number of
candidate signaling pathways that may be involved in
mediating and modulating the direct anti-proliferative
effect of GNRH agonists in vitro and in vivo. The
transcriptional and proteomic changes observed suggest
a model summarized in Fig. 7 where transcription factors
are increased as an early response and maintained
following Triptorelin treatment. Genes involved in
apoptosis (e.g. EIF5A and cFLAR) and G1/S transition
signaling (e.g. MCM8 and CHEK2) were altered in
expression around 1–8 h after treatment, whereas
expression of cytoskeletal (e.g. TPM4, ITGAV, DSTN,
MAPT and DGCR2) and G2/M-related (NDEL1, CDC2
(CDK1), TUBB4 (TUBB4A), DCTN1, KIF20A, CENPM,
CENPF, RASSF1A) genes were changed around 8–24 h.
The increased expression of early response genes such as
FOS and EGR1 after 30 min to 1 or 2 h was consistent with
previous observations of an intense and rapid increase in
ERK phosphorylation immediately following GNRHR
stimulation in SCL60 cells in vitro (Morgan et al. 2008),
translocation to the nucleus, and the activation of these
transcription factors. FOS gene family members encode
proteins that dimerize with proteins of the JUN family to
form the transcription factor complex AP-1 (Salisbury et al.
2008). The increased expression of both FOS and JUN
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Inhibition of NF-kB enhances the anti-proliferative effect of GNRH receptor
activation in HEK293 (SCL60). (A) The gene expression patterns of several
NF-kB pathway members were increased in the short term following
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family members make this a likely mechanism of
transcriptional activation in SCL60 cells.
Flow cytometric analysis suggested that Triptorelin
may induce G2/M arrest and accumulation in S phase after
24 and 48 h. A number of cell cycle genes are differentially
expressed, which may support this, particularly the
increase in MAD2 mitotic arrest deficient-like 1
(MAD2L1), which encodes a protein that forms part of
the spindle assembly checkpoint and prevents anaphase
until chromosomes are properly aligned. Another com-
ponent of the anaphase checkpoint, BUB3, was also
increased (Taylor et al. 1998), along with the growth arrest
and DNA-damage-inducible genes GADD45A and
GADD45B. These genes have been shown to activate the
p38/JNK pathway to cause G2/M arrest (Zhu et al. 2009,
Cho et al. 2010), and GADD45B has been shown to play a
role in mediating Fas-induced apoptosis by enhancing the
interaction between p38 and Rb (Cho et al. 2010). Several
cell cycle-related proteins were also differentially phos-
phorylated: p27kip and CDC25C were increased, while
Chk2 was decreased after 7 days. Changes in the
phosphorylation levels of the apoptosis regulators BCL2
and BAD were also observed.
Although ERK activation often drives proliferation, it
has been associated with cell death in many different cell
types (Zhuang & Schnellmann 2006, Mebratu & Tesfaigzi
2009). ERK-mediated G2 arrest is thought to be dependent
on PKC (Barboule et al. 1999, Dangi et al. 2006) and MEK1
(Dangi et al. 2006, Astuti et al. 2009). GNRHR signals
through Gaq to activate PLCb, causing PIP2 cleavage and
generation of DAG. IP3 activates calcium channels in the
endoplasmic reticulum to release Ca2C and PKC is
activated by DAG and Ca2C. Once active, PKC phosphor-
ylates Raf, which in turn activates MEK and downstream
ERK. We have previously shown that the GNRHR-
mediated anti-proliferative effect in SCL60 cells is depen-
dent on PKC (Morgan et al. 2008). The ERK activation
observed after Triptorelin treatment may be mediated
through PKC and may be responsible for the G2/M arrest
observed in SCL60 cells.
Later-stage (8–24 h) gene expression changes reflected
known GNRHR signaling effects exemplified by the CGA
transcript, a stress response (IL8) and growth modulation
(IGFBP5, FGFR, and Met). Changes in protein phospho-
rylation suggested modulation of membrane protein
function (Cav-1), growth signaling (Met), metabolism
(AMPK), cell motility (SRGAP3), and a pro-survival response
(NF-kB). Clearly, the status of the cell cycle apparatus was
altered with changes in p27, CDC25c, and Chk2.
NF-kB signaling was highlighted by both in vivo and
in vitro approaches; the additive effect of Triptorelin plus
15d-PGJ(2) on growth inhibition may represent a useful
target for drug combination treatments. Triptorelin has
previously been shown to induce NF-kB activation in
ovarian cancer cells (EFO-21 and EFO-27), which inhibited
doxorubicin-induced apoptosis (Grundker et al. 2000). As
15d-PGJ(2) elicits effects via PPAR-gamma and NF-kB, the
effect on growth in combination with Triptorelin may be
somewhat cell type specific. This phenomenon will
require further investigation. The results of the current
study indicate the intricacy of the regulatory response to
GNRHR activation. We found good agreement between
our gene expression data and a previous study of gene
expression changes in mouse LbT2 gonadotrope cells
following treatment with a GNRH agonist (Kakar et al.
2003). However, our recent findings that the overexpres-
sion of GNRHR alone is not sufficient to facilitate an anti-
proliferative response to Triptorelin in several breast
cancer cell lines (Morgan et al. 2011b) provides an
excellent opportunity to interrogate the factors and
mechanisms involved in cell-type-specific differences
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Figure 7
Model to summarize the anti-proliferative signaling response to a GNRH
agonist. (A) Overview of the major downstream signaling pathways
responding to Triptorelin identified by recent studies of transfected cells.
(B) Preliminary model of temporal changes in gene expression following
GNRH receptor activation in SCL60 cells indicating categories of genes such
as transcription factor cell cycles and cytoskeletal components. The shape
and volume of gray bars show approximate relative changes of gene
transcript levels from different functional categories over 24 h.
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that mediate the direct anti-proliferative effect of GNRH
agonists. These may entail analyses of the changes
occurring in WPE-1-NB26 cells, which exhibit cell cycle
arrest without prominent commitment to apoptosis and
manipulation of gene expression in MCF-7 cells, which
escape GNRHR-mediated growth inhibition.
In conclusion, in vitro and in vivo transcriptomic and
proteomic approaches were used to characterize the anti-
proliferative effects of a GNRH agonist at the molecular
signaling level. The anti-proliferative response induced by
GNRHR activation appears to result in apoptosis and G2/M
arrest mediated via a coordinated dynamic pattern of
MAPK, cell cycle, apoptotic, and cytoskeletal-related
signaling. Key regulators pAKT and pERK were repressed
and induced respectively, while pNF-kB was activated and
may represent a useful target for enhancing this intriguing
anti-proliferative response.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
ERC-12-0192.
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